Email RIS file
Bookmark
Report an Issue

Bispecific Antibody Pretargeting for Improving Cancer Imaging and Therapy [electronic resource].

Published
Washington, D.C. : United States. Dept. of Energy. Office of Energy Research, 2005.
Oak Ridge, Tenn. : Distributed by the Office of Scientific and Technical Information, U.S. Dept. of Energy.
Physical Description
6 pages : digital, PDF file
Additional Creators
United States. Department of Energy. Office of Energy Research and United States. Department of Energy. Office of Scientific and Technical Information
Access Online

Availability

I Want It
I Want It

Finding items...

Restrictions on Access
Free-to-read Unrestricted online access
Summary
The main objective of this project was to evaluate pretargeting systems that use a bispecific antibody (bsMAb) to improve the detection and treatment of cancer. A bsMAb has specificity to a tumor antigen, which is used to bind the tumor, while the other specificity is to a peptide that can be radiolabeled. Pretargeting is the process by which the unlabeled bsMAb is given first, and after a sufficient time (1-2 days) is given for it to localize in the tumor and clear from the blood, a small molecular weight radiolabeled peptide is given. According to a dynamic imaging study using a 99mTc-labeled peptide, the radiolabeled peptide localizes in the tumor in less than 1 hour, with > 80% of it clearing from the blood and body within this same time. Tumor/nontumor targeting ratios that are nearly 50 times better than that with a directly radiolabeled Fab fragment have been observed (Sharkey et al., ''Signal amplification in molecular imaging by a multivalent bispecific nanobody'' submitted). The bsMAbs used in this project have been composed of 3 antibodies that will target antigens found in colorectal and pancreatic cancers (CEA, CSAp, and MUC1). For the ''peptide binding moiety'' of the bsMAb, we initially examined an antibody directed to DOTA, but subsequently focused on another antibody directed against a novel compound, HSG (histamine-succinyl-glycine).
Report Numbers
E 1.99:doe/er/62028-1
doe/er/62028-1
Subject(s)
Other Subject(s)
Note
Published through SciTech Connect.
02/04/2005.
"doe/er/62028-1"
Sharkey, Robert M.
Center for Molecular Medicine and Immunology, Belleville, New Jersey
Type of Report and Period Covered Note
Final; 05/01/1995 - 11/30/2004
Funding Information
FG02-95ER62028
View MARC record | catkey: 13802225